Cosmo Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Cosmo Pharmaceuticals has a total shareholder equity of €433.6M and total debt of €559.0K, which brings its debt-to-equity ratio to 0.1%. Its total assets and total liabilities are €554.0M and €120.3M respectively. Cosmo Pharmaceuticals's EBIT is €12.2M making its interest coverage ratio 2.7. It has cash and short-term investments of €50.3M.
Key information
0.1%
Debt to equity ratio
€559.00k
Debt
Interest coverage ratio | 2.7x |
Cash | €50.28m |
Equity | €433.63m |
Total liabilities | €120.35m |
Total assets | €553.98m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 0RGI's short term assets (€102.2M) exceed its short term liabilities (€23.2M).
Long Term Liabilities: 0RGI's short term assets (€102.2M) exceed its long term liabilities (€97.2M).
Debt to Equity History and Analysis
Debt Level: 0RGI has more cash than its total debt.
Reducing Debt: 0RGI's debt to equity ratio has reduced from 35% to 0.1% over the past 5 years.
Debt Coverage: 0RGI's debt is well covered by operating cash flow (6014.8%).
Interest Coverage: 0RGI's interest payments on its debt are not well covered by EBIT (2.7x coverage).